Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)
Status:
Completed
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove the superiority of a 48-weeks treatment with 3.2 g/day
delayed-release phosphatidylcholine (LT-02) versus placebo for the maintenance of remission
in patients with ulcerative colitis (UC)